Balance Sheet Components (Tables)
 3 Months Ended
Mar. 31, 2014
Balance Sheet Components [Abstract]  
Summary of available for sale investments
The following table summarizes the Company's available for sale investments as of March 31, 2014 (in thousands).
 
 
Maturity (in Years)
 
Amortized Cost
 
Unrealized Gains
 
Unrealized Losses
 
Estimated Fair Value
Short-term investments:
 
 
 
 
 
 
 
 
 
 
   Commercial paper
 
1 or less
 
$
12,488

 
$
10

 
$
—

 
$
12,498

   Corporate debt securities
 
1 or less
 
20,214

 
—

 
(5
)
 
20,209

Total investments
 
 
 
$
32,702

 
$
10

 
$
(5
)
 
$
32,707

The following table summarizes the Company's available for sale investments as of December 31, 2013 (in thousands).
 
 
Maturity (in Years)
 
Amortized Cost
 
Unrealized Gains
 
Unrealized Losses
 
Estimated Fair Value
Short-term investments:
 
 
 
 
 
 
 
 
 
 
   Commercial paper
 
1 or less
 
$
15,232

 
$
14

 
$
—

 
$
15,246

   Corporate debt securities
 
1 or less
 
14,930

 
—

 
(9
)
 
14,921

      Total
 
 
 
30,162

 
14

 
(9
)
 
30,167

Long-term investments:
 
 
 
 
 
 
 
 
 
 
   Corporate debt securities
 
More than 1
 
1,514

 
—

 
(1
)
 
1,513

      Total
 
 
 
1,514

 
—

 
(1
)
 
1,513

Total investments
 
 
 
$
31,676

 
$
14

 
$
(10
)
 
$
31,680
Property and equipment components
Property and equipment, net were as follows (in thousands):
 
Useful Life
 
March 31,
 
December 31,
 
(in years)
 
2014
 
2013
Computer equipment and software
1.5 to 3 years
 
$
42

 
$
40

Office furniture and equipment
5 years
 
43

 
43

 
 
 
85

 
83

Accumulated depreciation
 
 
(34
)
 
(24
)
Property and equipment, net
 
 
$
51

 
$
59
Net book value of acquired intangible assets
The net book value of acquired intangible assets were as follows (in thousands):
 
March 31,
 
December 31,
Customer Agreements:
2014
 
2013
Cost
$
410

 
$
410

Accumulated amortization
(116
)
 
(75
)
Intangible assets, net
$
294

 
$
335

Weighted average remaining life (in years)
1.75
 
2.00
Schedule of accrued liabilities
Accrued liabilities were as follows (in thousands):
 
March 31,
 
December 31,
 
2014
 
2013
Accrued clinical trials
$
455

 
$
417

Accrued compensation
289

 
1,093

Accrued consulting
237

 
315

Other accrued liabilities
24

 
77

 
$
1,005

 
$
1,902